JP2016520112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520112A5 JP2016520112A5 JP2016516184A JP2016516184A JP2016520112A5 JP 2016520112 A5 JP2016520112 A5 JP 2016520112A5 JP 2016516184 A JP2016516184 A JP 2016516184A JP 2016516184 A JP2016516184 A JP 2016516184A JP 2016520112 A5 JP2016520112 A5 JP 2016520112A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- antidepressant
- reuptake inhibitor
- composition
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 13
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims 6
- 239000000935 antidepressant agent Substances 0.000 claims 6
- 229940005513 antidepressants Drugs 0.000 claims 6
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims 6
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 6
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 6
- 230000001430 anti-depressive effect Effects 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 4
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 3
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 3
- COCYGNDCWFKTMF-UHFFFAOYSA-N 7,8-DHF Natural products OC=1C(O)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 COCYGNDCWFKTMF-UHFFFAOYSA-N 0.000 claims 3
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 3
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 3
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 3
- 229960000959 amineptine Drugs 0.000 claims 3
- ONNOFKFOZAJDHT-UHFFFAOYSA-N amineptine Chemical compound C1CC2=CC=CC=C2C(NCCCCCCC(=O)O)C2=CC=CC=C21 ONNOFKFOZAJDHT-UHFFFAOYSA-N 0.000 claims 3
- 229960000836 amitriptyline Drugs 0.000 claims 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 3
- 239000003420 antiserotonin agent Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 229960001058 bupropion Drugs 0.000 claims 3
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 3
- 229960001653 citalopram Drugs 0.000 claims 3
- 229960003914 desipramine Drugs 0.000 claims 3
- 229960002866 duloxetine Drugs 0.000 claims 3
- 238000002635 electroconvulsive therapy Methods 0.000 claims 3
- 229960004341 escitalopram Drugs 0.000 claims 3
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 3
- 229960002464 fluoxetine Drugs 0.000 claims 3
- 229960004038 fluvoxamine Drugs 0.000 claims 3
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 3
- 229960004801 imipramine Drugs 0.000 claims 3
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 3
- 229960004644 moclobemide Drugs 0.000 claims 3
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 3
- 229960003991 trazodone Drugs 0.000 claims 3
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 3
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 3
- 229960004688 venlafaxine Drugs 0.000 claims 3
- 102000016938 Catalase Human genes 0.000 claims 2
- 108010053835 Catalase Proteins 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 108010053070 Glutathione Disulfide Proteins 0.000 claims 2
- 102000006587 Glutathione peroxidase Human genes 0.000 claims 2
- 108700016172 Glutathione peroxidases Proteins 0.000 claims 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000003859 lipid peroxidation Effects 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- 229960002748 norepinephrine Drugs 0.000 claims 2
- 238000013548 repetitive transcranial magnetic stimulation Methods 0.000 claims 2
- 238000011491 transcranial magnetic stimulation Methods 0.000 claims 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 claims 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- 108010063907 Glutathione Reductase Proteins 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 claims 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims 1
- 238000013542 behavioral therapy Methods 0.000 claims 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 238000011221 initial treatment Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- WHXSMMKQMYFTQS-BKFZFHPZSA-N lithium-12 Chemical compound [12Li] WHXSMMKQMYFTQS-BKFZFHPZSA-N 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000006318 protein oxidation Effects 0.000 claims 1
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13169936.5A EP2808023A1 (en) | 2013-05-30 | 2013-05-30 | New drug for the treatment and/or prevention of depressive disorders |
| EP13169936.5 | 2013-05-30 | ||
| PCT/EP2014/061240 WO2014191547A1 (en) | 2013-05-30 | 2014-05-30 | New drug for the treatment and/or prevention of depressive disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520112A JP2016520112A (ja) | 2016-07-11 |
| JP2016520112A5 true JP2016520112A5 (https=) | 2017-04-20 |
| JP6415545B2 JP6415545B2 (ja) | 2018-10-31 |
Family
ID=48520808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516184A Expired - Fee Related JP6415545B2 (ja) | 2013-05-30 | 2014-05-30 | 抑うつ障害の治療用及び／又は予防用の新規薬剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20160067231A1 (https=) |
| EP (2) | EP2808023A1 (https=) |
| JP (1) | JP6415545B2 (https=) |
| CA (1) | CA2910530A1 (https=) |
| WO (1) | WO2014191547A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6715568B2 (ja) * | 2015-01-22 | 2020-07-01 | 公益財団法人東京都医学総合研究所 | 睡眠異常をきたすうつ病のモデル動物 |
| TWI752282B (zh) * | 2017-11-22 | 2022-01-11 | 林潔欣 | 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途 |
| CN116870180B (zh) * | 2023-08-08 | 2026-04-21 | 中南大学湘雅医院 | 一种递送神经递质的纳米制剂及其制备方法与应用 |
| CN117904008B (zh) * | 2024-03-19 | 2024-06-11 | 山东中科嘉亿生物工程有限公司 | 一种预防和缓解抑郁的戊糖片球菌jypr-9187及其菌剂和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001030352A1 (en) * | 1999-10-28 | 2001-05-03 | Cary Pharmaceuticals Inc. | High dose folic acid for the treatment of hyperhomocysteinemia |
| US7758872B1 (en) * | 2003-02-07 | 2010-07-20 | Eric Finzi | Method of treating depression |
| ATE348818T1 (de) * | 2003-06-12 | 2007-01-15 | Btg Int Ltd | Cyclische hydroxylamine als psychoactive verbindugen |
| US20060039890A1 (en) * | 2004-08-20 | 2006-02-23 | Renshaw Perry F | Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant |
| US8969417B2 (en) * | 2008-06-06 | 2015-03-03 | Pharmatwob Ltd. | Pharmaceutical compositions for treatment of Parkinsons disease |
| US8778969B2 (en) | 2009-11-07 | 2014-07-15 | Peter H Proctor | Nitrone, nitroso, and nitroxide spintraps and spin labels and their hydroxylamines |
-
2013
- 2013-05-30 EP EP13169936.5A patent/EP2808023A1/en not_active Withdrawn
-
2014
- 2014-05-30 WO PCT/EP2014/061240 patent/WO2014191547A1/en not_active Ceased
- 2014-05-30 JP JP2016516184A patent/JP6415545B2/ja not_active Expired - Fee Related
- 2014-05-30 CA CA2910530A patent/CA2910530A1/en not_active Abandoned
- 2014-05-30 EP EP14728158.8A patent/EP3003308B1/en not_active Not-in-force
- 2014-05-30 US US14/787,328 patent/US20160067231A1/en not_active Abandoned
-
2018
- 2018-10-26 US US16/172,427 patent/US20190060298A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220069A1 (ar) | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها | |
| CN101861151B (zh) | 使用组蛋白脱乙酰基酶hdac1、hdac2和/或hdac3的选择性抑制剂和微管稳定剂的癌症组合治疗 | |
| JP2017509686A5 (https=) | ||
| JP2016520112A5 (https=) | ||
| JP2015535290A5 (https=) | ||
| JP6243698B2 (ja) | フラネオールによるにおいの抑制剤 | |
| RU2013108696A (ru) | ПРОИЗВОДНЫЕ ЦИС-ТЕТРАГИДРО-СПИРО(ЦИКЛОГЕСАН -1,1'-ПИРИДО[3,4-b]ИНДОЛ)-4-АМИНА | |
| JP2011523949A5 (https=) | ||
| DE602006021444D1 (de) | Therapie zur behandlung der überaktiven blase | |
| RU2008143550A (ru) | Комбинации терапевтических средств, предназначенные для лечения рака | |
| JP2015511609A5 (https=) | ||
| TNSN07145A1 (fr) | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique | |
| BRPI0610037A2 (pt) | derivados de dihidrobenzofurano e uso dos mesmos | |
| PE20080144A1 (es) | Compuestos de tetrahidropiridotienopirimidina con actividad antiproliferativa | |
| JP2017531689A5 (https=) | ||
| JP2016222706A (ja) | ブプレノルフィンおよびμ−オピオイド受容体アンタゴニストの組成物 | |
| CN114072404A (zh) | Ret选择性抑制剂及其制备方法和用途 | |
| RU2020125170A (ru) | Композиции и способы улучшения биодоступности 5-гидрокситриптофана | |
| JP2016537432A5 (https=) | ||
| WO2006130679B1 (en) | Composition and method for the treatment of allergic rhinitis | |
| JP6928000B2 (ja) | 化学療法の改善 | |
| TW200736189A (en) | Indene derivatives, their preparation and use as medicaments | |
| JP2017534652A5 (https=) | ||
| RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
| US6562858B2 (en) | Method for treating depression |